2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 214

Basic Calcium Phosphate Crystal Interactions with Tenocytes: An in Vitro Model of Calcific Tendinitis
Abstract Number: 215

Calcium Hydroxyapatite Crystals Inhibit Interleukin-6- and Interferon-γ –Induced Anti-Osteoclastogenic Signaling in Human Osteoclast Precursors
Abstract Number: 216

Effects of Monosodium Urate Crystals on Mlo-Y4 Cell Viability; Is There a Role for Osteocytes in Erosive Gout?
Abstract Number: 217

Circulating Levels of Neo-Epitopes Reflecting Connective Tissue Turnover As Biomarkers of Gout and Frequent Gout Attacks in Men
Abstract Number: 218

Diet-Wide Association Study of Serum Urate Levels in 13,782 Individuals of European Ancestry
Abstract Number: 219

Targeted Deep Resequencing Identifies MRP4/ABCC4 as a Gout Risk Locus in the New Zealand Mä�ori and Pacific Island Populations
Abstract Number: 220

A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout
Abstract Number: 221

Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study
Abstract Number: 222

Serum Delta Neutrophil Index Measurement for Differentiating Acute Gouty Arthritis and Cellulitis in Normouricemic Patients
Abstract Number: 223

Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Abstract Number: 224

Silent Monosodium Urate Crystals Deposits in Asymptomatic Hyperuricemia Lead to a Higher Need for Coronary Revascularization
Abstract Number: 225

Gout Patients Present Carotid Plaques at Presentation in Spite of Low-Risk Cardiovascular Score
Abstract Number: 226

Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Abstract Number: 227

Impact of Gout on the Risk of Atrial Fibrillation
Abstract Number: 228

Gout and Risk of Non-Vertebral Osteoporotic Fracture

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].